Pharm-Olam International Ltd., a multinational, full-service Clinical Research Organization (CRO) serving the biopharmaceutical and medical device industries, today announced the appointment of Daniel Burgess to the position of Senior Director, Quality and Compliance.
“In clinical trials, Quality Assurance and Compliance considerations go hand-in-hand,” said Sanjiv Suri, Chief Executive Officer, Pharm-Olam. “Over two decades, Pharm-Olam earned its reputation among drug developers as a high quality, responsive partner who can adapt its services to the unique requirements of each study. I’m confident Daniel will continue to lead that charge.”
Mr. Burgess’ extensive experience was a key factor in his appointment, Suri added. He brings to Pharm-Olam over 25 years of experience in the critical areas of quality assurance, quality control, auditing and compliance. Mr. Burgess’ resume includes progressive roles within several leading pharmaceutical industry organizations including Ipsen, Novartis, Alexion, Thermo Fisher Scientific and Pfizer.
Pharm-Olam operates in more than 60 countries worldwide, offering end-to-end clinical trial support for Phase I-IV clinical trials. More information about Pharm-Olam and its full-service capabilities and offerings are available at www.pharm-olam.com or contact us via email at email@example.com (link sends e-mail).
About Pharm-Olam International Group
Pharm-Olam International is a multinational Contract Research Organization (CRO) offering comprehensive clinical research services to the pharmaceutical, biotechnology and medical device industries. From Phase I to Phase IV, Pharm-Olam focuses on delivering the highest quality data, achieving targeted enrollment and meeting projected timelines, making clinical research as Easy As I, II, III, IV™. For further information about Pharm-Olam, please visit www.pharm-olam.com.